A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated chronic lymphocytic leukemia (CLL).
Herbert Aaron Eradat
Research Funding - Gilead Sciences
Tadeusz Robak
Research Funding - Gilead Sciences
Julio Delgado
Research Funding - Gilead Sciences
Anna Schuh
Research Funding - Gilead Sciences
Alexander S. Pristupa
Research Funding - Gilead Sciences
Joanna Omyla-Staszewska
Research Funding - Gilead Sciences
Jacqueline Claudia Barrientos
Research Funding - Gilead Sciences
Charles Michael Farber
Research Funding - Gilead Sciences
Donald MacDonald
Research Funding - Gilead Sciences
Abraham Jacob
Research Funding - Gilead Sciences
Jeff Porter Sharman
Research Funding - Gilead Sciences
Javier Loscertales
Research Funding - Gilead Sciences
Jennifer R. Brown
Research Funding - Gilead Sciences
Bertrand Coiffier
Research Funding - Gilead Sciences
Paolo Ghia
Research Funding - Gilead Sciences
Andrew David Zelenetz
Research Funding - Gilead Sciences
Shelley Evans
Employment or Leadership Position - Gilead Sciences
Stock Ownership - Gilead Sciences
Thomas Michael Jahn
Employment or Leadership Position - Gilead Sciences
Stock Ownership - Gilead Sciences
Michael J. Hallek
Research Funding - Gilead Sciences
Peter Hillmen
Research Funding - Gilead Sciences